Medical Devices Series B Investors & VC Firms
515 firms in this list, with a median first check of $540K. 108 of them lead rounds. Generated from verified public data and updated continuously.
Redesign Health
New YorkSeed–Late Stage
13 people
Luma Group
New YorkSeed–Growth
14 people
Esplanade Ventures
TorontoSeed–Series B
10 people
Yuanta Investment
SeoulSeed–Late Stage$1M – $15M
20 people
Outset Ventures
AucklandPre-Seed–Series B$100K – $10M
4 people
Tin Alley Ventures
MelbourneSeed–Late Stage
13 people
YZR Capital
MunichPre-Seed–Growth
12 people
Easton Capital
New YorkSeed–Series B$10M – $20M
7 people
Solasta Ventures
BostonSeed–Series B
6 people
Cross-Border Impact Ventures
TorontoSeries A–Series B$2M – $10M
11 people
Laerdal Million Lives Fund
San FranciscoSeries A–Series B$1M – $5M
9 people
Iyengar Capital Partners
ClaytonSeed–Series B
16 people
Mutual Capital Partners
WestlakeSeries A–Series C$1M
4 people
DC Investment Partners
McLeanSeed–Growth$10M
10 people
3xP Global
LisbonSeries A–Series B$1.1M – $10.8M
5 people
Maxpro Ventures
TaipeiSeed–Late Stage
7 people
Medical Incubator Japan K.K.
TokyoSeries A–Series B
11 people
Detong Capital
ShanghaiSeed–Growth$20M
11 people
Corner Ventures
New YorkSeed–Late Stage
15 people
HM Venture Partners
San FranciscoSeed–Growth
7 people
Dementia Discovery
LondonSeed–Series C
15 people
Gefen Capital
Herzliya PituachSeed–Series B
8 people
TVM Capital
MunichSeed–Late Stage$1.1M – $16.2M
10 people
Arc Angels
AucklandPre-Seed–Late Stage
Related lists
Series B Investors & VC Firms (2954)Series B Investors & VC Firms in North America (1744)Medical Devices Investors & VC Firms (1659)Series B Investors & VC Firms in United States (1578)Medical Devices Seed Investors & VC Firms (1321)Medical Devices Series A Investors & VC Firms (1139)Medical Devices Investors & VC Firms in North America (1090)Series B Investors & VC Firms in Europe (1078)SaaS Series B Investors & VC Firms (1075)Series B Investors & VC Firms in Global (1068)
Data sourced from public filings and firms' own websites — see our methodology.



















































































